Ionis Pharmaceuticals is an American biotechnology company headquartered in Carlsbad, California, founded in 1989 as ISIS Pharmaceuticals. The company is a pioneer in antisense oligonucleotide (ASO) therapeutics and has developed a leading platform for RNA-targeted drug discovery[1]. Ionis is best known for its strategic partnership with Biogen, which has led to multiple approved ASO therapies for neurological diseases including Tofersen (Qalsody) for SOD1-ALS and multiple programs in development for Alzheimer's and Parkinson's disease[2].
Founded by Dr. Stanley Crooke, Ionis (originally ISIS Pharmaceuticals) began as a pioneer in antisense technology, which uses short synthetic DNA sequences to bind to specific messenger RNA molecules and prevent them from being translated into proteins. The company's early work focused on genetic disorders, but its partnership with Biogen beginning in the early 2000s shifted focus toward neurological diseases[3].
The company's most significant achievement came with the development of Tofersen (brand name Qalsody), an ASO therapy for SOD1-mutated amyotrophic lateral sclerosis (ALS). In 2023, the FDA granted accelerated approval for Tofersen, making it the first ASO therapy to receive regulatory approval for a neurological disease outside of the spinal muscular atrophy (SMA) space[4].
Ionis maintains a robust neuroscience pipeline through its partnership with Biogen, with multiple programs in various stages of clinical development for Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions.
| Drug Name | Target | Mechanism | Indication | Phase | Status |
|---|---|---|---|---|---|
| Tofersen (Qalsody) | SOD1 | ASO - RNase H-mediated mRNA degradation | SOD1-ALS | Approved (2023) | Marketed |
| BIIB080 (Tau ASO) | MAPT | ASO - tau mRNA reduction | Alzheimer's Disease | Phase 2 | Active |
| BIIB132 (LRRK2 ASO) | LRRK2 | ASO - LRRK2 mRNA reduction | Parkinson's Disease | Phase 1 | Active |
| IONIS-MAPTRx | MAPT | ASO - tau protein reduction | Alzheimer's Disease | Phase 1/2 | Completed |
| IONIS-GBA2 | GBA | ASO - GCase modulation | Parkinson's Disease (GBA carriers) | Preclinical | Discovery |
| IONIS-C9orf72 | C9orf72 | ASO - repeat expansion targeting | ALS/FTD (C9orf72) | Phase 1 | Active |
| IONIS-HTT | HTT | ASO - huntingtin reduction | Huntington's Disease | Phase 1/2 | Active |
| IONIS-SOD1 | SOD1 | ASO - SOD1 reduction | ALS | Phase 3 | Completed |
| BIIB105 | ATXN2 | ASO - ataxin-2 reduction | ALS | Phase 1 | Active |
| IONIS-P2X7 | P2X7R | ASO - P2X7 receptor reduction | Neuroinflammation | Phase 1 | Active |
Ionis and Biogen are developing BIIB080, an antisense oligonucleotide targeting tau protein mRNA for Alzheimer's disease. Tau aggregation is a hallmark pathology in Alzheimer's, and reducing tau production represents a promising therapeutic approach[5]. The Phase 1 study demonstrated dose-dependent reduction in CSF tau protein, supporting advancement to Phase 2 trials.
Mutations in the LRRK2 gene are the most common genetic cause of Parkinson's disease. Ionis, in partnership with Biogen, is developing BIIB132, an ASO therapeutic designed to reduce LRRK2 protein expression in patients with pathogenic LRRK2 mutations[6].
BIIB132 Details:
| Attribute | Value |
|---|---|
| Target | LRRK2 mRNA |
| Mechanism | RNase H-mediated mRNA degradation |
| Phase | Phase 1 |
| NCT Number | NCT03976375 |
| Route | Intrathecal |
| Indication | Parkinson's disease (LRRK2 mutation carriers and sporadic PD) |
Development:
BIIB132 represents a complementary approach to small molecule LRRK2 kinase inhibitors (such as BIIB122 from the same Biogen-Denali partnership). While kinase inhibitors block LRRK2 enzymatic activity, ASOs reduce the amount of LRRK2 protein produced, offering potential for more complete pathway suppression[7].
For more detail, see LRRK2 Antisense Oligonucleotide Therapies.
The GBA gene encodes glucocerebrosidase, and mutations in this gene represent a significant risk factor for Parkinson's disease. ASO therapy targeting GBA represents a novel precision medicine approach for PD patients with GBA mutations[8].
Expansions in the C9orf72 gene are the most common cause of familial ALS and frontotemporal dementia (FTD). Ionis has developed ASOs targeting the repeat expansion RNA to reduce toxic gain-of-function effects[9].
Ionis' proprietary antisense technology platform enables the design of ASOs that specifically bind to target RNA sequences, leading to degradation of the target mRNA and reduced protein production. The company's advanced chemistries, including 2'-O-methoxyethyl (2'-MOE) and phosphorodiamidate morpholino oligomers (PMOs), improve drug delivery and efficacy[10].
| Mechanism | Description | Applications |
|---|---|---|
| RNase H-mediated degradation | ASO binds to target mRNA, RNase H cleaves the RNA strand | Most common mechanism for gene knockdown |
| Steric blockade | ASO blocks ribosomal translation without degrading mRNA | Splicing modulation, read-through |
| RISC-mediated | siRNA-like mechanism using Argonaute proteins | Gene silencing |
The VALOR trial demonstrated that Tofersen significantly reduced SOD1 protein levels in cerebrospinal fluid and showed a trend toward slowing clinical progression in patients with SOD1-mutated ALS[4:1]. The FDA granted accelerated approval based on biomarker reduction, making it a landmark approval for the ASO field in neurodegeneration.
Early-stage clinical trials for BIIB080 have shown dose-dependent reduction in tau protein in CSF, supporting continued development. The tau hypothesis posits that reducing tau may slow disease progression[5:1].
Ionis has maintained strong financial backing through its strategic partnerships and independent funding:
The strategic alliance between Ionis and Biogen, established in 2001, has been one of the most productive partnerships in neuroscience drug development. This partnership has yielded multiple approved drugs and a robust pipeline of neurological disease programs[2:1]. Key elements include:
Ionis' ASO programs target several key mechanisms in neurodegenerative diseases:
Bennett CF, et al. Therapeutic Antisense Oligonucleotides. Nat Rev Drug Discov. 2019. ↩︎
Biogen. Ionis Partnership. 2024. ↩︎ ↩︎
Crooke ST. The progression of the RNA-targeted therapeutics. Nat Rev Drug Discov. 2021. ↩︎
Miller T, et al. Tofersen for SOD1 ALS. N Engl J Med. 2022. ↩︎ ↩︎
Biogen. Tau ASO Program. 2024. ↩︎ ↩︎
Lang AE, et al. LRRK2 and Parkinson's Disease. Lancet Neurol. 2019. ↩︎
Borel F, et al. LRRK2 antisense oligonucleotides reduce protein levels and improve phenotypes in a Drosophila model. J Parkinsons Dis. 2018. ↩︎
Sidransky E, et al. GBA and Parkinson's Disease. Nat Rev Neurol. 2009. ↩︎
Jiang J, et al. C9orf72 ASO Therapy. Neuron. 2021. ↩︎
Geary RS, et al. Pharmacokinetics of phosphorodiamidate morpholino oligomers. Curr Opin Pharmacol. 2003. ↩︎